Request Demo
Last update 20 Mar 2025
PM-1009
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Action antagonists, inhibitors |
Mechanism CD112R antagonists(Transmembrane protein PVRIG antagonists), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization  Biotheus, Inc.Startup |
Active Organization Biotheus, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with PM-1009CTR20243205
评价PM8002注射液联合PM1009注射液治疗局部晚期或转移性肝细胞癌患者的初步疗效、安全性及药代动力学特征的Ib/II期临床试验
[Translation] A phase Ib/II clinical trial to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of PM8002 injection combined with PM1009 injection in the treatment of patients with locally advanced or metastatic hepatocellular carcinoma
NCT06584071
A Phase Ib/II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of PM8002 Injection Combined With PM1009 Injection in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT05607563
A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumors
100 Clinical Results associated with PM-1009
Login to view more data
100 Translational Medicine associated with PM-1009
Login to view more data
100 Patents (Medical) associated with PM-1009
Login to view more data
100 Deals associated with PM-1009
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatocellular Carcinoma | Phase 2 | China | Biotheus, Inc.Startup | 13 Dec 2024 |
| Metastatic hepatocellular carcinoma | Phase 2 | - | Biotheus, Inc.Startup | 01 Dec 2024 |
| Advanced cancer | Phase 1 | China | Biotheus, Inc.Startup | 17 Nov 2022 |
| Locally Advanced Hepatocellular Carcinoma | IND Approval | China | Biotheus, Inc.Startup | 10 Jul 2024 |
| Lung Cancer | IND Approval | China | Biotheus, Inc.Startup | 20 Sep 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 12 | (sxpidswxhs) = gaiegcdhtx fpcfnsytaa (ldyvhyjtwh, 9.92 - 65.11) View more | Positive | 24 May 2024 | |||
(sxpidswxhs) = enodsfatwa fpcfnsytaa (ldyvhyjtwh, 9.92 - 65.11) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free